Related Experiment Video
Updated: May 10, 2025
12:36
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
15.4K
Statin Use Is Associated With Protection Against Acute Cholangitis in Patients With Primary Sclerosing Cholangitis: A
Chiraag Kulkarni1, George Cholankeril2, Touran Fardeen1
1Division of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California, USA.
Clinical and Translational Gastroenterology
|April 24, 2025
Summary
Statins significantly reduce the risk of acute cholangitis in patients with primary sclerosing cholangitis (PSC). This study suggests statin therapy may be a beneficial preventative measure for cholangitis in PSC patients.
Area of Science:
- Hepatology
- Gastroenterology
- Clinical Pharmacology
Background:
- Primary sclerosing cholangitis (PSC) patients face a heightened risk of acute cholangitis.
- The epidemiological factors influencing cholangitis risk in PSC remain understudied.
- This research investigates the potential protective effect of statins against acute cholangitis in PSC.
Purpose of the Study:
- To determine the impact of statin use on the incidence of acute cholangitis in patients with PSC.
- To identify clinical factors associated with cholangitis development in PSC.
- To explore statins as a potential preventative strategy for cholangitis in PSC.
Main Methods:
- A multicenter, retrospective cohort study involving 294 PSC patients.
- Data analyzed from Stanford, Baylor, and Valley Medical Centers.
- Multivariable Cox regression used to identify risk factors for cholangitis.
Main Results:
- Fifty patients (17.0%) were on statin therapy.
- Statin use was associated with an 81% reduction in cholangitis risk (HR 0.19).
- Lower adjusted incidence of cholangitis at 36 months in statin users (2.8% vs 12.2%, P < 0.001).
- Statins also correlated with increased time-to-stricture (P = 0.004).
Conclusions:
- Statin therapy is linked to a decreased risk of cholangitis in PSC patients.
- Statins may delay the onset of dominant or high-grade strictures, a known PSC complication.
- Further research is warranted to confirm statins as a beneficial preventative therapy for cholangitis in PSC.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
465
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
465
01:29Chronic Pancreatitis II: Collaborative Care
48
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
48
01:17Chronic Bowel Disorders: Introduction
310
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
310
01:26Peptic Ulcer Disease IV: Management
49
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
49
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
325
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
325
01:30Acute Pancreatitis II: Clinical Manifestations and Management
71
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
71